Mindrank Therapeutics (Suzhou) New Drug Research & Development Co. Ltd. has divulged molecular glue degraders comprising cereblon (CRBN) ligands acting as dual eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) and casein kinase 1 isoform α (CSNK1A1) degradation inducers. They are reported to be potentially useful for the treatment of cancer, Alzheimer’s disease, inflammatory disorders, autoimmune diseases and metabolic diseases.
During the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, scientists from Plexium Inc. presented the identification of a new class of potent, selective, cereblon (CRBN)-based molecular glue degraders of CDK2 using its proprietary monovalent degrader platform.
Shanghai Leadingtac Pharmaceutical Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a GTPase KRAS (G12D mutant)-targeting moiety via a linker reported to be useful for the treatment of cancer.
Evopoint Biosciences Co. Ltd. has obtained clinical trial clearance in China for XNW-34017, an oral protein degrader that targets Aurora kinase A (AURKA) while simultaneously degrading MYC.
Evotec SE has received a $5 million milestone payment from Bristol Myers Squibb Co. (BMS), following the acceptance of an IND application by the FDA in the companies’ strategic protein degradation partnership.
Researchers at Triana Biomedicines Inc. presented the preclinical characterization of TRI-611, a CNS-penetrant molecular glue degrader targeting ALK in models of ALK fusion-positive non-small-cell lung cancer.
Researchers from Monte Rosa Therapeutics Inc. reported preclinical efficacy data on MRT-8102, a selective NEK7 molecular glue degrader, designed to treat inflammatory diseases.
Shanghai Leadingtac Pharmaceutical Co. Ltd. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a pan-KRAS-targeting moiety through a linker.
Simcere Pharmaceutical Co. Ltd. has synthesized proteolysis targeting chimeras (PROTACs) comprising E3 ubiquitin-protein ligands coupled to a signal transducer and activator of transcription 6 (STAT6)-targeting moiety via a linker reported to be useful for the treatment of cancer and inflammatory disorders.
RSS
